Patient Blood Management Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Patient Blood Management Market Trends and Insights

Rising Elective Surgical Volumes and Blood Conservation Priorities

Elective surgeries have surpassed pre-pandemic levels in many high-income healthcare systems, boosting demand in the patient blood management market. A 2025 study revealed that each unit of red blood cells used in elective non-cardiac surgeries added an average direct hospital cost of USD 491, representing 5.2% of the median total episode cost.^{[2]AABB, “AABB Survey Explores International PBM Practices,” AABB News, aabb.org} Hospitals are increasingly leveraging blood management teams as cost-control units, influencing capital approvals for monitoring and salvage systems. The 2024 EACTS and EACTAIC guidelines elevated point-of-care viscoelastic testing algorithms to essential tools in cardiac centers, driving demand for thromboelastography and ROTEM platforms and enhancing instrument utilization and consumable demand.^{[3]V. Rao et al., “The Transfusion of a Single Unit of Red Blood Cells Significantly Increases Total Hospital Costs in Adult, Non-cardiac Surgical Patients,” Scientific Reports, nature.com}

Preoperative Anemia Screening and Treatment Expands PBM Adoption

Preoperative anemia, affecting 25% to 35% of surgical patients, remains underdiagnosed and untreated, creating growth potential for the patient blood management market. Untreated anemia increases perioperative risks and reliance on transfusions. A 2025 study of 1,294 colorectal cancer patients showed intravenous iron protocols reduced postoperative transfusion rates to 10.7%, with compliance improving over time. Hospitals are shifting demand upstream to outpatient screening kits, iron therapy, and related accessories, boosting reagent and kit demand. AABB certification frameworks are helping integrate anemia screening into institutional workflows.

Value-Based Care and Transfusion Stewardship Pressure Hospitals to Standardize

Reimbursement systems rewarding fewer complications and shorter hospital stays are shaping the patient blood management market. The CMS Hospital Value-Based Purchasing Program redistributes 2% of base operating DRG payments based on quality performance, incentivizing practices that reduce transfusion-related complications and hospital stays.^{[4]Centers for Medicare and Medicaid Services, “FY 2026 Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System Proposed Rule Fact Sheet,” CMS, cms.gov} Hospitals are investing in analytics and decision support tools to prepare for reporting periods. SABM research linked patient blood management programs to ROI as high as 7:1, driven by reduced transfusion use, shorter stays, and lower costs per case. As these models expand beyond the United States, hospitals increasingly view transfusion stewardship platforms as essential infrastructure.

Expansion of Point-of-Care Testing for Rapid Blood Management Decisions

Point-of-care viscoelastic testing, including thromboelastography and rotational thromboelastometry, is becoming standard in cardiac, trauma, and orthopedic surgeries, expanding the patient blood management market. A 2026 review highlighted that viscoelastic test-guided hemostatic therapy reduces transfusion exposure, offsetting implementation costs. These tools are now used beyond operating rooms in pre-admission units and general wards, supporting restrictive transfusion practices. A 2025 AABB survey found 80.2% of respondents promoted single-unit transfusion strategies, increasing demand for bedside hemoglobin and coagulation confirmation tools. This broader application enhances recurring revenue per instrument as testing extends beyond high-acuity surgery suites.

High Upfront Cost of PBM Devices, Software, and Training

Capital expenditures remain a key barrier to expanding patient blood management (PBM), particularly for district and smaller community hospitals with limited budgets. In Germany, only 70 out of 2,000 hospitals participated in the national PBM network, reflecting financial and administrative challenges. A 2024 Oxford University study found that just 14.2% of NHS England hospitals implemented advanced clinical decision support for transfusion management, with financial constraints and limited senior engagement as major obstacles. Multi-year contracts bundled with instrument placements often obscure long-term costs, leading to underestimated consumable expenses and delayed rollouts. WHO guidance from 2025 suggests cost-effective scale-up strategies, but adoption timelines remain lengthy for many facilities.

Workflow Resistance Among Clinicians and Transfusion Committees

Workflow challenges continue to impede PBM adoption, even in hospitals that invest in software and decision support. A 2025 study in Turkey found only 30.3% physician compliance with a new clinical decision support system, citing time pressures and heavy workloads as key barriers. Experienced physicians showed higher engagement than junior clinicians, indicating that training alone does not close the implementation gap. Underutilization reduces software value and consumable demand, while large academic centers face deployment delays of 12 to 24 months due to complex stakeholder involvement. Accreditation pathways like AABB certification are aligning expectations, but adoption rates vary widely based on hospital culture and governance.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Instrument Dominance Masks Accelerating Reagent Pull-Through

In 2025, instruments accounted for 59.6% of the patient blood management market, driven by a decade of investments in automated blood analyzers, cell salvage systems, and viscoelastic testing platforms. Increased utilization of these systems is significantly enhancing reagent demand. Reagents and kits are projected to grow at an 8.76% CAGR through 2031, supported by rising anemia screenings, donor panels, and coagulation tests. Roche's 2026 launch of the cobas MPX-E assay highlights the market's shift toward workflow consolidation and higher reagent use per sample.

Software remains the smallest revenue segment in the patient blood management market, while accessories benefit from increased blood handling, separation, and apheresis activities in blood banks and hospitals. Accessories like blood bags, syringes, and vials see steady demand, particularly in Asia-Pacific and Latin America. Despite its smaller revenue base, software plays a strategic role in influencing instrument usage and adherence to transfusion protocols. Hospitals are adopting software for oversight, auditability, and aligning policies with daily transfusion practices.

By End User: Blood Banks Anchor Revenue While Hospitals Drive Protocol Complexity

Blood banks held a 56.77% share of the patient blood management market in 2025 and are expected to grow at an 8.45% CAGR through 2031. This growth is driven by simultaneous upgrades of aging systems and expanding donor screening requirements. WHO guidance in 2025 emphasized patient blood management's role in improving blood health and system control. Terumo Blood and Cell Technologies' launch of the Reveos Automated Blood Processing System in 2024 demonstrates the ongoing automation opportunities in blood center workflows.

Hospitals and clinics are the second-largest end users in the patient blood management market, with demand linked to expanding surgical services and PBM protocol integration. Diagnostic centers and labs follow, as anemia screenings and related tests shift to outpatient settings. The 'others' category is growing due to rising outpatient surgeries and broader adoption of blood management protocols. In the United States, the CMS Value-Based Purchasing framework incentivizes quality outcomes, reducing transfusion complications and hospital stays.

Geography Analysis

In 2025, North America accounted for 39.4% of the patient blood management market, driven by advanced healthcare infrastructure, high surgical volumes, and established stewardship governance. The United States leads regional demand due to a reimbursement framework linking hospital performance to transfusion safety and efficiency outcomes. PBM program adoption in North America reached 50.2% in 2025, up from 37.8% in 2013, with 80.2% of institutions promoting single-unit transfusion strategies. Canada supports market stability by aligning with U.S. clinical practices, while Mexico shows growing demand as PBM adoption expands. The region benefits from EHR-integrated decision support, increasing vendor retention in hospital workflows.

Europe remains a key player in the patient blood management market, with Germany, the United Kingdom, France, Italy, and Spain as major demand centers. Germany highlights significant potential, with only 70 of its 2,000 hospitals part of the national PBM network, leaving room for expansion. The 2024 cardiac surgery guidelines are formalizing viscoelastic testing across European cardiac centers, supporting structured replacement cycles for TEG and ROTEM platforms. Reimbursement structures vary, but markets like Germany show clear alignment between PBM outcomes, reduced complications, and improved hospital performance.

Asia-Pacific is projected to achieve the fastest growth in the patient blood management market, with a 7.23% CAGR through 2031. China drives this growth with revised regulations mandating patient-centered blood management protocols, preoperative anemia management, and autologous transfusion promotion. Its National Blood Management Information System is enhancing hospital demand for blood bank information systems and related software. India, Japan, Australia, and South Korea are scaling adoption due to aging populations and rising surgical volumes, while the GCC and parts of South America are gradually advancing blood bank automation.